Tibet Cheezheng Tibetan Medicine Co., Ltd.

Shenzhen Stock Exchange 002287.SZ

Tibet Cheezheng Tibetan Medicine Co., Ltd. EBIT for the year ending December 31, 2023: USD 99.91 M

Tibet Cheezheng Tibetan Medicine Co., Ltd. EBIT is USD 99.91 M for the year ending December 31, 2023, a 8.54% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Tibet Cheezheng Tibetan Medicine Co., Ltd. EBIT for the year ending December 31, 2022 was USD 92.05 M, a 6.21% change year over year.
Tibet Cheezheng Tibetan Medicine Co., Ltd. EBIT for the year ending December 31, 2021 was USD 86.67 M, a 21.43% change year over year.
Tibet Cheezheng Tibetan Medicine Co., Ltd. EBIT for the year ending December 31, 2020 was USD 71.37 M, a 22.35% change year over year.
Tibet Cheezheng Tibetan Medicine Co., Ltd. EBIT for the year ending December 31, 2019 was USD 58.33 M, a 12.57% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 002287.SZ

Tibet Cheezheng Tibetan Medicine Co., Ltd.

CEO	Mr. Kailie Liu
IPO Date	Aug. 28, 2009
Location	China
Headquarters	2 Tibet Nyingchi Deji Road
Employees	3,091
Sector	Health Care
Industries Pharmaceuticals

Description

Tibet Cheezheng Tibetan Medicine Co., Ltd. together with its subsidiaries, engages in the research, development, production, and sale of Tibetan medicine in China. It provides drug products in the areas of cardiovascular, respiratory, digestive, urinary and reproductive system, nervous system, musculoskeletal system, and gynecological disorders. The company was founded in 1995 and is based in Nyingchi, China. Tibet Cheezheng Tibetan Medicine Co., Ltd. operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd.

Key trends

Past 5 years